Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis

Completed · Phase 2

Conditions studied: Dermatitis, Atopic

In brief

The purpose of this study is to determine the safety and efficacy of AN2728 Topical Ointment, 2% and 0.5%, administered once a day (QD) or twice a day (BID), in the treatment of adolescents with atopic dermatitis (AD)

Key facts

Study ID

NCT01602341

Run by

Pfizer

People needed

86

Starts

2012-08-01

Expected to finish

2013-01-01

Last updated by the study team

2017-03-06

Who can join

Age: 12 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female 12 to 17 years of age, inclusive
• Clinical diagnosis of atopic dermatitis (according to the criteria of Hanifin and Rajka)
• Total body surface area (BSA) of atopic dermatitis involvement ≤35%
• Presence of two comparable target lesions
• Willing and able to comply with study instructions and commit to attending all visits
• Females of childbearing potential must use a highly effective method of birth control. Males with partners of childbearing potential should inform them of their participation in this clinical study and use a highly effective method of birth control during the study.
• Parent/guardian has the ability to understand, agree to and sign the study Informed Consent Form (ICF) prior to initiation of any protocol-related procedures; subject has the ability to give assent

You may not qualify if…

• Significant confounding conditions as assessed by study doctor
• Unstable or actively infected AD
• Active or potentially recurrent dermatologic condition other than atopic dermatitis in the target lesion area that may confound evaluation
• History or evidence of allergies requiring acute or chronic treatment (except seasonal allergic rhinitis)
• Concurrent or recent use of certain topical or systemic medications or phototherapy without a sufficient washout period
• Treatment for any type of cancer (except squamous cell carcinoma, basal cell carcinoma, or carcinoma in situ of the skin, curatively treated with cryosurgery or surgical excision only) within the last 5 years
• Current pregnancy or lactation, or intent to become pregnant during the study
• Known sensitivity to any of the components of the study drug
• Participated in any other trial of an investigational drug or device within 30 days or participation in a research study concurrent with this study
• Participated in a previous AN2728 clinical study

Where it is running

• Anacor Investigational Site — Fremont, California, United States
• Anacor Investigational Site — Miami, Florida, United States
• Anacor Investigational Site — Lousiville, Kentucky, United States
• Anacor Investigational Site — Detroit, Michigan, United States
• Anacor Investigational Site — Albuquerque, New Mexico, United States
• Anacor Investigational Site — Stony Brook, New York, United States
• Anacor Investigational Site — High Point, North Carolina, United States
• Anacor Investigational Site — Portland, Oregon, United States
• Anacor Investigational Site — Knoxville, Tennessee, United States
• Anacor Investigational Site — Salt Lake City, Utah, United States
• Anacor Investigational Site — Norfolk, Virginia, United States
• Anacor Investigational Site — Phillip, Australian Capital Territory, Australia
• Anacor Investigational Site — Kogarah, New South Wales, Australia
• Anacor Investigational Site — Wooloongabba, Queensland, Australia
• Anacor Investigational Site — Box Hill, Victoria, Australia
• Anacor Investigational Site — Parkville, Victoria, Australia
• Anacor Investigational Site — Fremantle, Western Australia, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.